All news

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Spyre Therapeutics has announced a proposed underwritten public offering of common stock to secure funding for its ongoing development programs. The proceeds will primarily support advancing its Gastroenterology, Rheumatology, and Dermatology programs through clinical stages, including Phase 3 readiness, and initiating late-stage development for SPY072 in hidradenitis suppurativa. The offering's completion is contingent on market and other conditions.

Read original source

SYRE company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.